Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan's Astellas to Market New Immunosuppressive Drug Advagraf in Germany, UK (Japan)

This article was originally published in PharmAsia News

Executive Summary

Japan's third largest pharmaceutical company Astellas Pharma will begin selling new immuno-suppressive product Advagraf for use during renal transplants in Germany and Britain on June 18. The company also is seeking Advagraf's approval in Japan and the United States. Astellas sells this once-per-day drug featuring tacrolimus as a way to treat symptoms of organ rejection in adult patients. Astellas' twice-per-day version, Prograf, is already used for liver and kidney transplant patients. (Click here for more

You may also be interested in...



Astellas’ Once-Daily Tacrolimus Again “Approvable” For Kidney Transplant Patients

Astellas Pharma received a second U.S. FDA "approvable" letter for use of its long-lasting immunosuppressant FK506 in kidney transplant patients, the company said March 14.

WHO Prequalifies Celltrion’s Rituximab

Celltrion's Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the World Health Organization.

Medac Will Market Fresenius Kabi’s Adalimumab In Germany

Fresenius Kabi’s Idacio biosimilar adalimumab rival to Humira will from the start of June be marketed in Germany by Medac, following a deal between the two companies.

UsernamePublicRestriction

Register

PL007508

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel